Ocugen (OCGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Jul, 2026Executive summary
Special Meeting scheduled for September 21, 2026, with voting available online or virtually.
Shareholders are asked to consider key proposals affecting the company's capital structure.
Voting matters and shareholder proposals
Proposal to amend the Certificate of Incorporation to increase authorized common stock by 250,000,000 shares.
Proposal to approve adjournment of the meeting if more time is needed to solicit votes for the share increase.
Board recommends voting in favor of both proposals.
Shareholder rights and capital structure
Proposed amendment would significantly expand the number of authorized shares, impacting potential future equity issuances.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ocugen
- Shareholders will vote to increase authorized shares to support growth and commercialization.OCGN
Proxy filing - Pivotal gene therapy trials for RP and Stargardt aim for global launches by 2028.OCGNCanaccord Genuity's 46th Annual Growth Conference
- FDA cleared OCU410 phase III; $130M financing extends cash runway to 2028 amid going concern risk.OCGNQ2 2026
- Vote sought to increase authorized shares by 250M to support growth and strategic flexibility.OCGNProxy filing
- Vote sought to increase authorized shares by 250 million to support growth and financing flexibility.OCGNProxy filing
- Late-stage gene therapies for major retinal diseases advance toward global approvals by 2028.OCGNPiper Sandler Virtual Ophthalmology Day
- Gene-agnostic therapies show strong safety, efficacy, and major market potential in retinal diseases.OCGNStatus Update
- Gene therapy pipeline advances and $65M financing extend cash runway into Q1 2026, but funding risks persist.OCGNQ3 2024
- Gene therapy trials advanced, net loss narrowed, and $32.6M raised to extend cash runway.OCGNQ2 2024